Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Regeneron allays competition fears for 'gold standard' eye drug, shares rise

Economy Aug 03, 2022 12:06PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: The Regeneron Pharmaceuticals company logo is seen on a building at the company's Westchester campus in Tarrytown, New York, U.S. September 17, 2020. Picture taken September 17, 2020. REUTERS/Brendan McDermid/File Photo

By Mrinalika Roy

(Reuters) -Regeneron Pharmaceuticals said on Wednesday it expects demand for blockbuster eye drug Eylea to remain strong in the third quarter even in the face of emerging competition from rival drugs, sending the company's shares up nearly 8%.

Analysts earlier this year flagged competition concerns for Eylea from newly launched Roche Holding AG (OTC:RHHVF)'s Vabysmo, as both belong to the same class of drugs, called anti-VEGF.

"Despite new competition, Eylea's share was approximately half of the anti-VEGF category, affirming its status as the gold standard," Regeneron (NASDAQ:REGN) Chief Executive Officer Leonard Schleifer said.

U.S. sales of Eylea, which has dominated the market for treatments for eye diseases such as macular degeneration, jumped 14% to $1.62 billion in the second quarter ended June 30.

"Ongoing demographic trends such as the aging population and prevalence of diabetes support anticipated mid to high single-digit category growth for the foreseeable future," said senior Regeneron executive Marion McCourt.

Shares of the company rose 8.3% to $622.30 in mid day trading.

The company is testing high-dose Eylea in two chronic eye diseases, with data expected in the later half of 2022.

Wells Fargo (NYSE:WFC) analyst Mohit Bansal says the data will be "the most important catalyst" for the company, as the high dosage has the potential to make Eylea sustainable for a longer term.

Regeneron's anti inflammatory drug, Dupixent, recorded sales growth of nearly 40% in the quarter.

The company's quarterly revenue fell 44% to $2.86 billion, but came in ahead of analysts' expectation of $2.80 billion.

The fall was due to the U.S. regulator's decision to limit the use of Regeneron's COVID-19 antibody drug in January in all states due to its lack of effectiveness against the Omicron variant.

Regeneron said the U.S. Food and Drug Administration's review of application for the drug's full approval in certain patients was ongoing.

Regeneron allays competition fears for 'gold standard' eye drug, shares rise
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email